{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:47:52Z","timestamp":1792277272269,"version":"4.4.0"},"reference-count":54,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2018,1,11]],"date-time":"2018-01-11T00:00:00Z","timestamp":1515628800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0191244","type":"journal-article","created":{"date-parts":[[2018,1,11]],"date-time":"2018-01-11T15:27:46Z","timestamp":1515684466000},"page":"e0191244","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":39,"title":["Comprehensive molecular profiling of advanced\/metastatic olfactory neuroblastomas"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5653-4007","authenticated-orcid":true,"given":"Jasmina","family":"Topcagic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anatole","family":"Ghazalpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Swensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoran","family":"Gatalica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semir","family":"Vranic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,1,11]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s12105-009-0125-2","article-title":"Olfactory neuroblastoma","volume":"3","author":"LD Thompson","year":"2009","journal-title":"Head Neck Pathol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/hed.20920","article-title":"Esthesioneuroblastoma: The Princess Margaret Hospital experience","volume":"30","author":"G Bachar","year":"2008","journal-title":"Head Neck"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S1470-2045(01)00558-7","article-title":"Esthesioneuroblastoma: a meta-analysis and review","volume":"2","author":"P Dulguerov","year":"2001","journal-title":"Lancet Oncol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/hed.20127","article-title":"Olfactory neuroblastoma: the 22-year experience at one comprehensive cancer center","volume":"27","author":"EM Diaz Jr.","year":"2005","journal-title":"Head Neck"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/PAP.0b013e3181b544cf","article-title":"Olfactory neuroblastoma: a review and update","volume":"16","author":"H Faragalla","year":"2009","journal-title":"Adv Anat Pathol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1002\/lary.23641","article-title":"Treatment modalities and outcomes of olfactory neuroblastoma","volume":"122","author":"CM Song","year":"2012","journal-title":"Laryngoscope"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11060-008-9645-y","article-title":"Retrospective review of adjuvant chemotherapy for esthesioneuroblastoma","volume":"90","author":"AB Porter","year":"2008","journal-title":"J Neurooncol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"14771","DOI":"10.3390\/ijms140714771","article-title":"Clinical advances in molecular biomarkers for cancer diagnosis and therapy","volume":"14","author":"S Sethi","year":"2013","journal-title":"Int J Mol Sci"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cancergencyto.2006.09.024","article-title":"Comprehensive cytogenetic characterization of an esthesioneuroblastoma","volume":"173","author":"H Holland","year":"2007","journal-title":"Cancer Genet Cytogenet"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/modpathol.2008.57","article-title":"Array comparative genomic hybridization analysis of olfactory neuroblastoma","volume":"21","author":"M Guled","year":"2008","journal-title":"Mod Pathol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/gcc.22288","article-title":"Comparative genomic hybridization on microarray (a-CGH) in olfactory neuroblastoma: Analysis of ten cases and review of the literature","volume":"54","author":"R Valli","year":"2015","journal-title":"Genes Chromosomes Cancer"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1750-3639.2004.tb00048.x","article-title":"CGH pattern of esthesioneuroblastoma and their metastases","volume":"14","author":"U Bockmuhl","year":"2004","journal-title":"Brain Pathol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"e37029","DOI":"10.1371\/journal.pone.0037029","article-title":"Paired tumor and normal whole genome sequencing of metastatic olfactory neuroblastoma","volume":"7","author":"GJ Weiss","year":"2012","journal-title":"PLoS One"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12885-016-2209-1","article-title":"Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis","volume":"16","author":"S Cha","year":"2016","journal-title":"BMC Cancer"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"e3536","DOI":"10.1097\/MD.0000000000003536","article-title":"Recurrent Olfactory Neuroblastoma Treated With Cetuximab and Sunitinib: A Case Report","volume":"95","author":"L Wang","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1634\/theoncologist.2016-0287","article-title":"Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options","volume":"22","author":"LM Gay","year":"2017","journal-title":"Oncologist"},{"key":"ref17","article-title":"Comprehensive Molecular Profiling of Olfactory Neuroblastoma Identifies Potentially Targetable FGFR3 Amplifications","author":"L Lazo de la Vega","year":"2017","journal-title":"Mol Cancer Res"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"52584","DOI":"10.18632\/oncotarget.9683","article-title":"Genetic and molecular alterations in olfactory neuroblastoma: implications for pathogenesis, prognosis and treatment","volume":"7","author":"P Czapiewski","year":"2016","journal-title":"Oncotarget"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.clbc.2015.04.008","article-title":"Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications","volume":"15","author":"SZ Millis","year":"2015","journal-title":"Clin Breast Cancer"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1158\/1055-9965.EPI-14-0654","article-title":"Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type","volume":"23","author":"Z Gatalica","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.18632\/oncotarget.6421","article-title":"Multiplatform molecular profiling identifies potentially targetable biomarkers in malignant phyllodes tumors of the breast","volume":"7","author":"Z Gatalica","year":"2016","journal-title":"Oncotarget"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5858\/arpa.2013-0953-SA","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"138","author":"AC Wolff","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/CAD.0000000000000021","article-title":"ERCC1 expression levels predict the outcome of platinum-based chemotherapies in advanced bladder cancer: a meta-analysis","volume":"25","author":"S Li","year":"2014","journal-title":"Anticancer Drugs"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2007.15.5580","article-title":"Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial","volume":"26","author":"MS Braun","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref25","first-page":"999","article-title":"Is class III beta-tubulin a true predictive marker of sensitivity to vinorelbine in non-small cell lung cancer? Chemosensitivity data evidence","volume":"31","author":"Y Hirai","year":"2011","journal-title":"Anticancer Res"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1200\/JCO.2009.26.5983","article-title":"Pilot study using molecular profiling of patients\u2019 tumors to find potential targets and select treatments for their refractory cancers","volume":"28","author":"DD Von Hoff","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/tbj.12380","article-title":"Refractory angiosarcoma of the breast with VEGFR2 upregulation successfully treated with sunitinib","volume":"21","author":"E Silva","year":"2015","journal-title":"Breast J"},{"key":"ref28","first-page":"27","article-title":"Tumor molecular profiling in the treatment of refractory cancers","volume":"11","author":"KC Birendra","year":"2015","journal-title":"J Exp Ther Oncol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.devcel.2009.06.016","article-title":"Wnt\/beta-catenin signaling: components, mechanisms, and diseases","volume":"17","author":"BT MacDonald","year":"2009","journal-title":"Dev Cell"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1186\/1471-2407-13-537","article-title":"Wnt signaling in triple negative breast cancer is associated with metastasis","volume":"13","author":"N Dey","year":"2013","journal-title":"BMC Cancer"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/2052-8426-2-28","article-title":"Targeting the Wnt pathways for therapies","volume":"2","author":"A Blagodatski","year":"2014","journal-title":"Mol Cell Ther"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"552","DOI":"10.18632\/oncotarget.191","article-title":"Drug discovery approaches to target Wnt signaling in cancer stem cells","volume":"1","author":"JC Curtin","year":"2010","journal-title":"Oncotarget"},{"key":"ref33","first-page":"413","article-title":"Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis","volume":"22","author":"JH Lee","year":"2013","journal-title":"J Gastrointestin Liver Dis"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1136\/jcp.2007.047043","article-title":"Molecular alterations of KIT and PDGFRA in GISTs: evaluation of a Portuguese series","volume":"61","author":"AL Gomes","year":"2008","journal-title":"J Clin Pathol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1158\/1078-0432.CCR-14-0720","article-title":"CHK it out! Blocking WEE kinase routs TP53 mutant cancer","volume":"20","author":"JE Bauman","year":"2014","journal-title":"Clin Cancer Res"},{"key":"ref36","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317699800","article-title":"ABC gene expression profiles have clinical importance and possibly form a new hallmark of cancer","volume":"39","author":"P Dvorak","year":"2017","journal-title":"Tumour Biol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.biopha.2012.11.011","article-title":"Microarray-based detection and expression analysis of ABC and SLC transporters in drug-resistant ovarian cancer cell lines","volume":"67","author":"R Januchowski","year":"2013","journal-title":"Biomed Pharmacother"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2217\/pgs.13.26","article-title":"The expression profile of ATP-binding cassette transporter genes in breast carcinoma","volume":"14","author":"V Hlavac","year":"2013","journal-title":"Pharmacogenomics"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1186\/s12885-015-1689-8","article-title":"Frequent down-regulation of ABC transporter genes in prostate cancer","volume":"15","author":"R Demidenko","year":"2015","journal-title":"BMC Cancer"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/2162-3619-2-26","article-title":"ABC transporter activity linked to radiation resistance and molecular subtype in pediatric medulloblastoma","volume":"2","author":"WJ Ingram","year":"2013","journal-title":"Exp Hematol Oncol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"70ra13","DOI":"10.1126\/scitranslmed.3001845","article-title":"Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans","volume":"3","author":"J Guevara-Aguirre","year":"2011","journal-title":"Sci Transl Med"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway","volume":"375","author":"VA Boussiotis","year":"2016","journal-title":"N Engl J Med"},{"key":"ref43","doi-asserted-by":"crossref","DOI":"10.3390\/genes8060151","article-title":"MYC Deregulation in Primary Human Cancers","volume":"8","author":"M Kalkat","year":"2017","journal-title":"Genes (Basel)"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1182\/blood.V95.6.2104","article-title":"c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover","volume":"95","author":"F Bahram","year":"2000","journal-title":"Blood"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1126\/science.6719137","article-title":"Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage","volume":"224","author":"GM Brodeur","year":"1984","journal-title":"Science"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"e000023","DOI":"10.1136\/esmoopen-2015-000023","article-title":"NTRK gene fusions as novel targets of cancer therapy across multiple tumour types","volume":"1","author":"A Amatu","year":"2016","journal-title":"ESMO Open"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1158\/1078-0432.CCR-13-1486","article-title":"PBX1 is a favorable prognostic biomarker as it modulates 13-cis retinoic acid-mediated differentiation in neuroblastoma","volume":"20","author":"N Shah","year":"2014","journal-title":"Clin Cancer Res"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1042\/BJ20081834","article-title":"High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours","volume":"416","author":"H Caren","year":"2008","journal-title":"Biochem J"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11060-009-0027-x","article-title":"Disease stabilization of progressive olfactory neuroblastoma (esthesioneuroblastoma) under treatment with sunitinib mesylate","volume":"97","author":"M Preusser","year":"2010","journal-title":"J Neurooncol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"e12513","DOI":"10.1200\/jco.2011.29.15_suppl.e12513","article-title":"Imatinib mesylate as second-line treatment in a c-kit positive esthesioneuroblastoma","volume":"29","author":"SA Kim","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"ref51","first-page":"P153","article-title":"Nove targeted treatment combinations for malignant neuroendocrine tumour olfactory neuroblastoma","volume":"38","author":"K Young","year":"2015","journal-title":"Endocrine Abstr"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.3892\/etm.2016.3732","article-title":"Lutetium 177-DOTA-TATE therapy for esthesioneuroblastoma: A case report","volume":"12","author":"JG Sabongi","year":"2016","journal-title":"Exp Ther Med"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000236047","article-title":"Activation of sonic hedgehog signaling pathway in olfactory neuroblastoma","volume":"77","author":"L Mao","year":"2009","journal-title":"Oncology"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"5620","DOI":"10.1200\/jco.2004.22.14_suppl.5620","article-title":"Successful treatment of a patient with unresectable olfactory neuroblastoma: a case report and literature review","volume":"22","author":"LJ Bhupalam","year":"2004","journal-title":"Journal of Clinical Oncology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0191244","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,25]],"date-time":"2020-10-25T10:13:25Z","timestamp":1603620805000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0191244"}},"subtitle":[],"editor":[{"given":"Chandan","family":"Kumar-Sinha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,1,11]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,1,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0191244","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,11]]}}}